Miltefosine is an alkylphosphocholine drug with demonstrated activity against various
parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 …

Leishmaniasis is one of the most neglected tropical disease in terms of drug discovery and
development. Most antileishmanial drugs are highly toxic, present resistance issues or …

Abstract Background. Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is
currently the first-line therapy in the VL elimination program of the Indian subcontinent …

Leishmaniasis is a neglected tropical disease that affects about 350 million individuals
worldwide. The protozoan parasite has a relatively simple life cycle with two principal …

The increase of many deadly diseases like infections by multidrug-resistant bacteria implies
re-inventing the wheel on drug discovery. A better comprehension of the metabolisms and …

The ability to screen compounds in a high-throughput manner is essential in the process of
small molecule drug discovery. Critical to the success of screening strategies is the proper …

This paper describes the development of poly (D, L-lactide-co-glycolide)(PLGA)
nanoparticles (NPs) and nanosuspensions with the polyene antibiotic amphotericin B …

Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …

Visceral leishmaniasis is a neglected tropical disease with significant health impact. The
current treatments are poor, and there is an urgent need to develop new drugs. Primary …

Leishmaniasis is a tropical disease threatening 350 million people from endemic regions.
The available drugs for treatment are inadequate, with limitations such as serious side …